A synergistic non-toxic formulation for management of respiratory pathogens including coronaviruses and the process of preparing the synergistic formulation. The effective, non-toxic composition comprises of biological peptides including calcium chelating peptide and zinc chelating peptides, protease inhibitor such as 9-Arginine-peptide and inhibitor of viral replication enzyme such as vitamin B12 to reduce the presence of respiratory viruses including coronaviruses. The formulation is a cocktail of ingredients having a synergistic effect which is capable of being administered through various means including by way of inhalation, as nasal spray or an oral pump or via nebulizer to inhibit the entry and replication of respiratory pathogens. The combination of the formulation is such that it can be customized for a number of viral infections. The formulation is economical, self-administrable and effective even in low doses.

The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro).sub.n-His-Pro-His-Ala-Arg-Ile-Lys].sub.m-Y. The peptides are for medical use, in particular as anti-tumoral agents.

The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro).sub.n-His-Pro-His-Ala-Arg-Ile-Lys].sub.m-Y. The peptides are for medical use, in particular as anti-tumoral agents.

The present invention provides a novel pharmaceutical composition for treating dry eye syndrome. The composition significantly alleviates corneal damage and corneal opacity without side effects, thereby restoring damaged corneas and increasing tear secretion, and thus effectively treats ophthalmic diseases related to dry eye syndrome.

The present invention provides a novel pharmaceutical composition for treating dry eye syndrome. The composition significantly alleviates corneal damage and corneal opacity without side effects, thereby restoring damaged corneas and increasing tear secretion, and thus effectively treats ophthalmic diseases related to dry eye syndrome.

The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm Hg or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm Hg to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).

A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to α-melanocortin stimulating hormone (α-MSH).

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.